Secretin: Pancreatitis Trial on Pirfenidone Recruiting, Phase 2

As of July 29, 2026, a clinical trial associated with secretin is listed as recruiting. The study, registered as NCT06253117, is titled "Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis." It is designated a Phase 2 trial. The current status recorded for this trial is recruiting, meaning the study is open to enrolling participants as of the date listed. No results have been posted for this trial according to the available record. The trial registration does not specify additional outcome data at this time. Secretin, which carries approved regulatory status, is referenced in connection with this trial listing though the study title centers on pirfenidone as the therapeutic strategy under evaluation. Readers should note that recruiting status indicates the trial is active and seeking participants, not that any conclusions have been reached about safety or effectiveness. Further updates to this trial's status, including changes to recruitment or the eventual posting of results, would be expected to appear in future updates to the registration record at the provided clinical trial identifier. For more background on secretin itself, readers can consult the compound overview.